Pure Global AI
NCT06273917Not yet recruiting

Deprescribing Potentially Inappropriate Medications in the Emergency Department for Persons Living With Dementia

National Institute on Aging (NIA)ClinicalTrials.govother
Verified
Study focus
Disease/Condition
Dementia
Drug/Device/Intervention
PRIDE
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
National Institute on Aging (NIA)
Location
Chicago,Lake Forest,Palos Heights, United States of America
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2024
End date
Jan 01, 2025
Enrollment
290 participants
Primary outcome

Pharmacist communication of deprescribing recommendation

Summary

Aim 1: To demonstrate the feasibility by determining proportion of completed medication
 reconciliation, Central Nervous System active Potentially Inappropriate Medication (CNS PIM)
 use among patients with Alzheimer's Disease and Related Dementias (ADRD) and Mild Cognitive
 Impairment (MCI) in the emergency department (ED), and communication between ED clinical
 pharmacists and outpatient prescribers.
 
 Aim 2: To demonstrate the feasibility of collecting the primary and secondary outcomes for a
 subsequent study. The future primary outcome will be reduction in CNS PIMs 90 days after an
 ED visit. Secondary outcomes will include outpatient follow-up, repeat ED visits, and
 hospitalizations during the 90 days following an ED visit.
 
 Aim 3: To demonstrate the acceptability of the PRIDE intervention to outpatient clinicians
 using the Acceptability of Intervention Measure and qualitative analysis of responses.

ICD-10 classifications
Unspecified dementiaAlzheimer diseaseDementia in Alzheimer diseaseDementia in Alzheimer disease, unspecifiedDementia in other diseases classified elsewhere
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06273917
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06273917 through Pure Global AI's free database. This phase not specified trial is sponsored by National Institute on Aging (NIA) and is currently Not yet recruiting. The study focuses on Dementia. Target enrollment is 290 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.